SCHEMBL335477

SCHEMBL335477

c1ccc(COc2ccc(N3CCNCC3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 5/20 0.64
SLC6A2 P23975 3/20 0.60
SLC6A3 Q01959 3/20 0.60
HTR1A P08908 2/20 0.60
SLC6A4 P31645 2/20 0.60
PRMT5 O14744 5/20 0.58
HTR3E A5X5Y0 2/20 0.58
HTR3B O95264 2/20 0.58
ADRB1 P08588 2/20 0.58
HTR3A P46098 2/20 0.58
HTR3D Q70Z44 2/20 0.58
HTR3C Q8WXA8 2/20 0.58
SIGMAR1 Q99720 2/20 0.58
EGFR P00533 1/20 0.55
HTR6 P50406 1/20 0.53
LMNA P02545 2/20 0.50
MAOB P27338 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2156238 0.98 LTA4H (0.62) LTA4HSLC6A2SLC6A3HTR1ASLC6A4
SCHEMBL5230479 0.94 LTA4H (0.57) LTA4HSLC6A2SLC6A3HTR1ASLC6A4
SCHEMBL22638141 0.87 KIT (0.57) LTA4HSLC6A2SLC6A3HTR1ASLC6A4
Phenylpiperazine SCHEMBL11463313 0.86 LTA4H (0.64) LTA4HHTR1ASIGMAR1LMNAALDH1A1
SCHEMBL16046663 0.85 LTA4H (0.62) LTA4HSLC6A2SLC6A3LMNAMAOB
SCHEMBL4676367 0.85 ADRB2 (0.60) LTA4HSLC6A2SLC6A3HTR1ASLC6A4
SCHEMBL4671546 0.85 ADRB1 (0.59) LTA4HSLC6A2SLC6A3HTR1ASLC6A4
SCHEMBL12916421 0.85 ADRB1 (0.65) LTA4HPRMT5HTR3EHTR3BADRB1
SCHEMBL13904125 0.84 HTR3A (0.61) LTA4HSLC6A2SLC6A3HTR1ASLC6A4
SCHEMBL9047395 0.84 LTA4H (0.60) LTA4HSLC6A2SLC6A3EGFRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11925637-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use SRX CARDIO, LLC (US) 2024-03-12 US claimed
US-20220047582-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE SRX CARDIO, LLC 2022-02-17 US claimed
US-10980801-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use SRX CARDIO, LLC (US) 2021-04-20 US claimed
US-20200253958-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE SRX CARDIO, LLC 2020-08-13 US claimed
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery UNIV JOHNS HOPKINS (US) 2026-04-02 US disclosed
US-12527746-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2026-01-20 US disclosed
EP-4642434-A2 LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2025-11-05 EP disclosed
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same Life Technologies Corporation (US) 2025-11-04 US disclosed
US-12371522-B2 Bioreducible poly (beta-amino ester)s for siRNA delivery THE JOHNS HOPKINS UNIVERSITY (US) 2025-07-29 US disclosed
US-20250136737-A1 MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS THE JOHNS HOPKINS UNIVERSITY 2025-05-01 US disclosed
US-20240263196-A1 Lipid Compositions and Methods for Delivery to Immune Cells Life Technologies Corporation 2024-08-08 US disclosed
US-12049530-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERISTY (US) 2024-07-30 US disclosed
WO-1999011651-A2 3-DESCLADINOSE 6-O-SUBSTITUDED ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1999-03-11 WO disclosed
US-5866549-A MACROLIDE ANTIBIOTICS ABBOTT LABORATORIES (US) 1999-02-02 US disclosed
WO-1998032748-A1 SULFAMIDE-METALLOPROTEASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 1998-07-30 WO disclosed
EP-0836599-A1 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES PHARMACIA & UPJOHN COMPANY (US) 1998-04-22 EP disclosed
WO-1998009978-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 1998-03-12 WO disclosed
WO-1997042206-A1 6-O-SUBSTITUTED ERYTHROMYCIN COMPOUNDS AND METHOD FOR MAKING SAME ABBOTT LABORATORIES (US) 1997-11-13 WO disclosed
WO-1997002259-A1 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES PHARMACIA & UPJOHN COMPANY (US) 1997-01-23 WO disclosed
US-4616086-A ANTICOAGULANTS BOEHRINGER MANNHEIM GMBH (DE) 1986-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200253958-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE PCSK9, LDLR, PCSK7 LTA4H 1131/4885SLC6A2 4641/4885SLC6A3 4726/4885
US-12527746-B2 Peptide/particle delivery systems VEGFA, IGF2BP2, MSTN LTA4H 4760/4885SLC6A2 3113/4885SLC6A3 3476/4885
US-20250136737-A1 MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS PEF1, FIBP, PARN LTA4H 3932/4885SLC6A2 3748/4885SLC6A3 3778/4885
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same SNRPA, NUDT21, SOAT2 LTA4H 982/4885SLC6A2 429/4885SLC6A3 1409/4885
US-20220047582-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE PCSK9, LDLR, PCSK7 LTA4H 1131/4885SLC6A2 4641/4885SLC6A3 4726/4885
US-12371522-B2 Bioreducible poly (beta-amino ester)s for siRNA delivery AARS1, SLC43A1, PHAX LTA4H 3275/4885SLC6A2 1007/4885SLC6A3 1274/4885
US-12049530-B2 Multicomponent degradable cationic polymers PEF1, FIBP, PARN LTA4H 3932/4885SLC6A2 3748/4885SLC6A3 3778/4885
US-10980801-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use PCSK9, LDLR, PCSK7 LTA4H 1131/4885SLC6A2 4641/4885SLC6A3 4726/4885
US-11925637-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use PCSK9, LDLR, PCSK7 LTA4H 1131/4885SLC6A2 4641/4885SLC6A3 4726/4885
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery SLC43A1, SLC7A5, SLC7A1 LTA4H 4480/4885SLC6A2 749/4885SLC6A3 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.